Expression and tumoricidal activity of a human-mouse chimeric anti-DR5 antibody through a Furin/2A peptide

National Medical Journal of China

Volumn 91, Issue 10, 2011, Pages 707-710

  Li, Meng ^a   Lü, Fu Jia ^a   Shi, Juan ^a   Liu, Yan Xin ^a   Zheng, De Xian ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Chimeric antibody, DR5; Furin 2A peptide; Lentiviral vector; Neoplasms; Therapy

Indexed keywords

DR5 ANTIBODY; FURIN; LENTIVIRUS VECTOR; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; ANTINEOPLASTIC AGENT; HYBRID PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL STRAIN HEK293; CELL VIABILITY; CHIMERA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; HEAVY CHAIN; LIGHT CHAIN; OPEN READING FRAME; PEPTIDE ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FURIN; GENETIC VECTORS; HEK293 CELLS; HUMANS; MICE; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 84869856152     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2011.10.015     Document Type: Article

References (9)

1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3: 673-682.
2. Guo Y, Chen C, Zheng Y, et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem, 2005, 280: 41940-41952.
3. Zhu J, Paul WE. CD4 + T cell plasticity-Th2 cells join the crowd. Immunity, 2010, 32: 11-13.
4. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med, 2000, 6: 564-567
5. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res, 2004, 14: 359-372.
6. Mahalingam D, Szegezdi E, Keane M, et al. TRAIL receptor signalling and modulation; are we on the right TRAIL? Cancer Treat Rev, 2009, 35: 280-288.
7. Fang J, Qian JJ, Yi S, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol, 2005, 23: 584-590.
8. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 1997, 90: 2188-2195.
9. 1998: 78.